Pregled bibliografske jedinice broj: 1050163
Effect of fenofibrate on plasma apolipoprotein C- III levels: a systematic review and meta- analysis of randomised placebo-controlled trials
Effect of fenofibrate on plasma apolipoprotein C- III levels: a systematic review and meta- analysis of randomised placebo-controlled trials // BMJ Open, 8 (2018), 11; 1-9 doi:10.1136/bmjopen-2018-021508 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1050163 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Effect of fenofibrate on plasma apolipoprotein C-
III levels: a systematic review and meta- analysis
of randomised placebo-controlled trials
Autori
Sahebkar, Amirhossein ; Simental-Mendía, Luis E ; Katsiki, Niki ; Reiner, Željko ; Banach, Maciej ; Pirro, Matteo ; Atkin, Stephen L
Izvornik
BMJ Open (2044-6055) 8
(2018), 11;
1-9
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
fenofibrate ; fibrate ; apolipoprotein C ; meta-analysis
Sažetak
Objectives This meta-analysis of randomised placebo-controlled clinical trials aimed to assess the effect of fenofibrate on apolipoprotein C-III (apo C-III), a key regulator of triglyceride metabolism. Materials and methods Randomised placebo- controlled trials investigating the impact of fenofibrate treatment on apo C-III levels were searched in PubMed-Medline, Scopus, Web of Science and Google Scholar databases from inception to 18 August 2017. Quantitative data synthesis was determined by a random-effects model and generic inverse variance method. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate glycaemic parameter confounders. Results Meta-analysis of 10 clinical trials involving 477 subjects showed fenofibrate therapy decreased apo C-III levels (weighted mean difference (WMD) -4.78mg/dL, 95% CI -6.95 to -2.61, p<0.001 ; I(2)66.87%). Subgroup analysis showed that fenofibrate reduced plasma apo C-III concentrations in subgroups of trials with treatment durations of either <12 weeks (WMD -4.50mg/dL, p=0.001) or 12 weeks (WMD: -4.73mg/dL, p=0.009) and doses of fenofibrate <200mg/day (WMD -6.33mg/dL, p<0.001) and >200mg/day (p=0.006), with no significant difference between the subgroups. Conclusion This meta-analysis found that fenofibrate therapy significantly decreases apo C-III levels, an effect evident with both short-term treatment and doses less than 200mg/day.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb
Profili:
Željko Reiner
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE